<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005523'>Lymphoproliferative disorders</z:hpo> (LPDs) are generally caused by uncontrolled B-cell proliferation induced by the Epstein-Barr virus (EBV) in the setting of impaired EBV-specific T-cell immunity, particularly when there is pharmacological immunosuppression including antithymocyte globulin </plain></SENT>
<SENT sid="1" pm="."><plain>We herein present an unusual case of EBV associated with LPD (EBV-LPD) in which LPD occurred 3 weeks after the use of rabbit antithymocyte globulin administered for severe <z:hpo ids='HP_0012115'>hepatitis</z:hpo>-associated <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>; the patient died of fulminant leukemic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 5 days after the <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We also review the pertinent literature on EBV-LPD after immunosuppressive therapy and document the efficacy of EBV <z:mp ids='MP_0001799'>viral</z:mp> load monitoring and the need for preemptive therapy </plain></SENT>
</text></document>